JASON A BERNER
- Type
- Physician · Allopathic & Osteopathic Physicians / Internal Medicine / Endocrinology, Diabetes & Metabolism
- Where
- JASPER, GA
- NPI
- 1144201781
- Received
- $484,893 in 1,865 records, 2019 to 2025 ($457,106 general, $27,786 research)
- As principal investigator
- $1,924,161 of research payments to others in 393 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 119 | $24,062 |
| 2024 | General payment | 185 | $47,118 |
| 2024 | Research payment | 12 | $1,800 |
| 2023 | General payment | 197 | $47,051 |
| 2023 | Research payment | 1 | $6,482 |
| 2022 | General payment | 301 | $73,570 |
| 2022 | Research payment | 2 | $19,504 |
| 2021 | General payment | 238 | $28,667 |
| 2020 | General payment | 300 | $65,389 |
| 2019 | General payment | 510 | $171,246 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 273 | $328,143 |
| Travel and Lodging | 228 | $51,972 |
| Food and Beverage | 1,296 | $30,200 |
| Compensation for serving as faculty or as a speaker for a medical education program | 21 | $30,049 |
| Research payment | 15 | $27,786 |
| Consulting Fee | 11 | $12,180 |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing | 5 | $3,600 |
| Honoraria | 1 | $600 |
| Education | 14 | $300 |
| Gift | 1 | $59 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-19 | Amgen Inc. | $16 | Food and Beverage | In-kind items and services | TEPEZZA Biological, Inflammation/Rare Disease | 2025 | |
| 2025-12-16 | KYOWA KIRIN, INC. | $20 | Food and Beverage | In-kind items and services | CRYSVITA Drug, FIBROBLAST GROWTH FACTOR 23 FGF23 BLOCKING ANTIBODY | 2025 | |
| 2025-12-15 | Madrigal Pharmaceuticals | $34 | Food and Beverage | In-kind items and services | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-12-02 | Tandem Diabetes Care, Inc. | $23 | Food and Beverage | In-kind items and services | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2025 | |
| 2025-11-18 | Ascendis Pharma Endocrinology Inc | $24 | Food and Beverage | In-kind items and services | Yorvipath Drug, Endocrinology | 2025 | |
| 2025-11-13 | Abbott Laboratories | $46 | Food and Beverage | In-kind items and services | FREESTYLE LIBRE 3 Device, Diabetes Care | 2025 | |
| 2025-11-12 | Organon Llc | $18 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-11-06 | Corcept Therapeutics | $27 | Food and Beverage | In-kind items and services | Korlym Drug, Endocrinology | 2025 | |
| 2025-11-04 | Madrigal Pharmaceuticals | $22 | Food and Beverage | In-kind items and services | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-11-04 | Novo Nordisk Inc | $8 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2025 | |
| 2025-11-03 | Madrigal Pharmaceuticals | $34 | Food and Beverage | In-kind items and services | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-10-30 | Amgen Inc. | $15 | Food and Beverage | In-kind items and services | TEPEZZA Biological, Inflammation/Rare Disease | 2025 | |
| 2025-10-28 | Boehringer Ingelheim Pharmaceuticals, Inc. | $18 | Food and Beverage | In-kind items and services | JARDIANCE Drug, DIABETES | 2025 | |
| 2025-10-28 | Acella Pharmaceuticals, LLC | $16 | Food and Beverage | In-kind items and services | NP Thyroid 60 Drug, Hypothyroidism | 2025 | |
| 2025-10-23 | BETA BIONICS, INC. | $24 | Food and Beverage | In-kind items and services | iLet Bionic Pancreas Device, Automated insulin delivery system | 2025 | |
| 2025-10-23 | Insulet Corporation | $22 | Food and Beverage | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2025 | |
| 2025-10-22 | Antares Pharma, Inc. | $20 | Food and Beverage | In-kind items and services | XYOSTED Drug, TESTOSTERONE REPLACEMENT THERAPY | 2025 | |
| 2025-10-21 | Novo Nordisk Inc | $19 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2025 | |
| 2025-10-20 | Mannkind Corporation | $16 | Food and Beverage | In-kind items and services | AFREZZA Drug, DIABETES MEDICINE | 2025 | |
| 2025-10-14 | Sequel Med Tech, LLC | $19 | Food and Beverage | In-kind items and services | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | 2025 | |
| 2025-10-13 | Abbott Laboratories | $17 | Food and Beverage | In-kind items and services | FREESTYLE LIBRE 3 Device, Diabetes Care | 2025 | |
| 2025-09-22 | Merck Sharp & Dohme LLC | $25 | Education | In-kind items and services | Drug, CARDIOVASCULAR | 2025 | |
| 2025-09-22 | Amgen Inc. | $15 | Food and Beverage | In-kind items and services | TEPEZZA Biological, Inflammation/Rare Disease | 2025 | |
| 2025-09-18 | Merck Sharp & Dohme LLC | $77 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-09-17 | Antares Pharma, Inc. | $22 | Food and Beverage | In-kind items and services | XYOSTED Drug, TESTOSTERONE REPLACEMENT THERAPY | 2025 | |
| 2025-09-15 | Dexcom, Inc. | $130 | Travel and Lodging | Cash or cash equivalent | DEXCOM G7 GSS (161) Medical Supply, Endocrinology | 2025 | |
| 2025-09-15 | Dexcom, Inc. | $3 | Travel and Lodging | Cash or cash equivalent | DEXCOM G7 GSS (161) Medical Supply, Endocrinology | 2025 | |
| 2025-09-11 | Ascendis Pharma Endocrinology Inc | $20 | Food and Beverage | In-kind items and services | Yorvipath Drug, Endocrinology | 2025 | |
| 2025-09-10 | KYOWA KIRIN, INC. | $20 | Food and Beverage | In-kind items and services | CRYSVITA Drug, FIBROBLAST GROWTH FACTOR 23 FGF23 BLOCKING ANTIBODY | 2025 | |
| 2025-09-09 | Mannkind Corporation | $24 | Food and Beverage | In-kind items and services | AFREZZA Drug, DIABETES MEDICINE | 2025 | |
| 2025-09-09 | Novo Nordisk Inc | $12 | Food and Beverage | In-kind items and services | Wegovy Drug, Obesity | 2025 | |
| 2025-08-26 | Novo Nordisk Inc | $20 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2025 | |
| 2025-08-25 | Dexcom, Inc. | $1,915 | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | DEXCOM G7 GSS (161) Medical Supply, Endocrinology | 2025 | |
| 2025-08-22 | Novo Nordisk Inc | $23 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-08-19 | Boehringer Ingelheim Pharmaceuticals, Inc. | $19 | Food and Beverage | In-kind items and services | JARDIANCE Drug, DIABETES | 2025 | |
| 2025-08-16 | Dexcom, Inc. | $125 | Food and Beverage | In-kind items and services | DEXCOM G7 GSS (161) Medical Supply, Endocrinology | 2025 | |
| 2025-08-13 | Amgen Inc. | $18 | Food and Beverage | In-kind items and services | REPATHA Biological, Cardiovascular | 2025 | |
| 2025-08-12 | Novo Nordisk Inc | $23 | Food and Beverage | In-kind items and services | Wegovy Drug, Obesity | 2025 | |
| 2025-08-12 | Corcept Therapeutics | $23 | Food and Beverage | In-kind items and services | Korlym Drug, Endocrinology | 2025 | |
| 2025-08-07 | Antares Pharma, Inc. | $20 | Food and Beverage | In-kind items and services | XYOSTED Drug, TESTOSTERONE REPLACEMENT THERAPY | 2025 | |
| 2025-08-06 | Neurocrine BioSciences, Inc. | $30 | Food and Beverage | In-kind items and services | CRENESSITY Drug, Neuropsychiatry | 2025 | |
| 2025-08-05 | Ascendis Pharma Endocrinology Inc | $18 | Food and Beverage | In-kind items and services | Yorvipath Drug, Endocrinology | 2025 | |
| 2025-07-30 | Lilly USA, LLC | $800 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-07-30 | Lilly USA, LLC | $14 | Food and Beverage | In-kind items and services | MOUNJARO Drug, Diabetes | 2025 | |
| 2025-07-24 | Novartis Pharmaceuticals Corporation | $18 | Food and Beverage | In-kind items and services | LEQVIO Drug, Cardiology/Vascular Diseases | 2025 | |
| 2025-07-24 | Mannkind Corporation | $13 | Food and Beverage | In-kind items and services | AFREZZA Drug, DIABETES MEDICINE | 2025 | |
| 2025-07-17 | Neurocrine BioSciences, Inc. | $30 | Food and Beverage | In-kind items and services | CRENESSITY Drug, Neuropsychiatry | 2025 | |
| 2025-07-14 | Amgen Inc. | $18 | Food and Beverage | In-kind items and services | TEPEZZA Biological, Inflammation/Rare Disease | 2025 | |
| 2025-07-13 | Mannkind Corporation | $148 | Food and Beverage | In-kind items and services | AFREZZA Drug, DIABETES MEDICINE | 2025 | |
| 2025-07-13 | Lilly USA, LLC | $32 | Food and Beverage | In-kind items and services | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-07-09 | Antares Pharma, Inc. | $21 | Food and Beverage | In-kind items and services | XYOSTED Drug, TESTOSTERONE REPLACEMENT THERAPY | 2025 | |
| 2025-07-02 | SANOFI-AVENTIS U.S. LLC | $26 | Food and Beverage | In-kind items and services | TZIELD Biological, Endocrine & Metabolic Diseases | 2025 | |
| 2025-06-27 | Dexcom, Inc. | $2,298 | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | DEXCOM G7 GSS (161) Medical Supply, Endocrinology | 2025 | |
| 2025-06-25 | Dexcom, Inc. | $2,681 | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | DEXCOM G7 GSS (161) Medical Supply, Endocrinology | 2025 | |
| 2025-06-25 | Dexcom, Inc. | $1,723 | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | DEXCOM G7 GSS (161) Medical Supply, Endocrinology | 2025 | |
| 2025-06-25 | Dexcom, Inc. | $301 | Travel and Lodging | Cash or cash equivalent | DEXCOM G7 GSS (161) Medical Supply, Endocrinology | 2025 | |
| 2025-06-21 | Dexcom, Inc. | $111 | Food and Beverage | In-kind items and services | DEXCOM G7 GSS (161) Medical Supply, Endocrinology | 2025 | |
| 2025-06-21 | Dexcom, Inc. | $24 | Food and Beverage | In-kind items and services | DEXCOM G7 GSS (161) Medical Supply, Endocrinology | 2025 | |
| 2025-06-19 | Lilly USA, LLC | $22 | Food and Beverage | In-kind items and services | JARDIANCE Drug, Diabetes | 2025 | |
| 2025-06-17 | Boehringer Ingelheim Pharmaceuticals, Inc. | $21 | Food and Beverage | In-kind items and services | JARDIANCE Drug, DIABETES | 2025 | |
| 2025-06-14 | Dexcom, Inc. | $551 | Travel and Lodging | In-kind items and services | DEXCOM G7 GSS (161) Medical Supply, Endocrinology | 2025 | |
| 2025-06-13 | Dexcom, Inc. | $160 | Food and Beverage | In-kind items and services | DEXCOM G7 GSS (161) Medical Supply, Endocrinology | 2025 | |
| 2025-06-11 | Ascendis Pharma Endocrinology Inc | $22 | Food and Beverage | In-kind items and services | Yorvipath Drug, Endocrinology | 2025 | |
| 2025-06-04 | Tandem Diabetes Care, Inc. | $27 | Food and Beverage | In-kind items and services | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2025 | |
| 2025-05-29 | SANOFI-AVENTIS U.S. LLC | $23 | Food and Beverage | In-kind items and services | TZIELD Biological, Endocrine & Metabolic Diseases | 2025 | |
| 2025-05-21 | KYOWA KIRIN, INC. | $20 | Food and Beverage | In-kind items and services | CRYSVITA Drug, FIBROBLAST GROWTH FACTOR 23 FGF23 BLOCKING ANTIBODY | 2025 | |
| 2025-05-21 | Novo Nordisk Inc | $19 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2025 | |
| 2025-05-19 | Mannkind Corporation | $20 | Food and Beverage | In-kind items and services | AFREZZA Drug, DIABETES MEDICINE | 2025 | |
| 2025-05-16 | Boehringer Ingelheim Pharmaceuticals, Inc. | $800 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | JARDIANCE Drug, DIABETES | 2025 | |
| 2025-05-16 | BETA BIONICS, INC. | $24 | Food and Beverage | In-kind items and services | iLet Bionic Pancreas Device, Automated insulin delivery system | 2025 | |
| 2025-05-06 | Ascendis Pharma Endocrinology Inc | $20 | Food and Beverage | In-kind items and services | Yorvipath Drug, Endocrinology | 2025 | |
| 2025-05-06 | Novo Nordisk Inc | $17 | Food and Beverage | In-kind items and services | Wegovy Drug, Obesity | 2025 | |
| 2025-05-01 | Medtronic, Inc. | $23 | Food and Beverage | In-kind items and services | MINIMED 780G Device, Durable Pump | 2025 | |
| 2025-04-30 | Sequel Med Tech, LLC | $19 | Food and Beverage | In-kind items and services | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | 2025 | |
| 2025-04-28 | Amgen Inc. | $21 | Food and Beverage | In-kind items and services | TEPEZZA Biological, Inflammation/Rare Disease | 2025 | |
| 2025-04-24 | SANOFI-AVENTIS U.S. LLC | $27 | Food and Beverage | In-kind items and services | TZIELD Biological, Endocrine & Metabolic Diseases | 2025 | |
| 2025-04-23 | Radius Health, Inc. | $19 | Food and Beverage | In-kind items and services | Tymlos Drug, Endocrinology | 2025 | |
| 2025-04-22 | Xeris Pharmaceuticals, Inc. | $24 | Food and Beverage | In-kind items and services | RECORLEV Drug, Adrenal steroidogenesis inhibitor | 2025 | |
| 2025-04-21 | Lilly USA, LLC | $18 | Food and Beverage | In-kind items and services | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-04-15 | Lilly USA, LLC | $800 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | JARDIANCE Drug, Diabetes | 2025 | |
| 2025-04-15 | Novo Nordisk Inc | $22 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2025 | |
| 2025-04-13 | Mannkind Corporation | $16 | Food and Beverage | In-kind items and services | AFREZZA Drug, DIABETES MEDICINE | 2025 | |
| 2025-04-02 | Ascendis Pharma Endocrinology Inc | $20 | Food and Beverage | In-kind items and services | Yorvipath Drug, Endocrinology | 2025 | |
| 2025-04-01 | CeQur Corporation | $17 | Food and Beverage | Cash or cash equivalent | CeQur Simplicity Device, Diabetes | 2025 | |
| 2025-03-26 | Ascendis Pharma Endocrinology Inc | $121 | Food and Beverage | In-kind items and services | Yorvipath Drug, Endocrinology | 2025 | |
| 2025-03-25 | Novo Nordisk Inc | $27 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2025 | |
| 2025-03-24 | Lilly USA, LLC | $800 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | JARDIANCE Drug, Diabetes | 2025 | |
| 2025-03-21 | Lilly USA, LLC | $800 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | JARDIANCE Drug, Diabetes | 2025 | |
| 2025-03-20 | Insulet Corporation | $20 | Food and Beverage | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2025 | |
| 2025-03-20 | Amgen Inc. | $14 | Food and Beverage | In-kind items and services | REPATHA Biological, Cardiovascular | 2025 | |
| 2025-03-19 | Sequel Med Tech, LLC | $25 | Food and Beverage | In-kind items and services | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | 2025 | |
| 2025-03-18 | Boehringer Ingelheim Pharmaceuticals, Inc. | $20 | Food and Beverage | In-kind items and services | JARDIANCE Drug, DIABETES | 2025 | |
| 2025-03-14 | BETA BIONICS, INC. | $24 | Food and Beverage | In-kind items and services | iLet Bionic Pancreas Device, Automated insulin delivery system | 2025 | |
| 2025-03-12 | SANOFI-AVENTIS U.S. LLC | $24 | Food and Beverage | In-kind items and services | TZIELD Biological, Endocrine & Metabolic Diseases | 2025 | |
| 2025-03-12 | Tandem Diabetes Care, Inc. | $17 | Food and Beverage | In-kind items and services | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2025 | |
| 2025-03-11 | Lilly USA, LLC | $1,200 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | JARDIANCE Drug, Diabetes | 2025 | |
| 2025-03-07 | Dexcom, Inc. | $306 | Travel and Lodging | In-kind items and services | DEXCOM G7 GSS (161) Medical Supply, Endocrinology | 2025 | |
| 2025-03-06 | Mannkind Corporation | $42 | Education | In-kind items and services | AFREZZA Drug, DIABETES MEDICINE | 2025 | |
| 2025-03-06 | Mannkind Corporation | $9 | Food and Beverage | In-kind items and services | AFREZZA Drug, DIABETES MEDICINE | 2025 | |
| 2025-03-05 | Xeris Pharmaceuticals, Inc. | $23 | Food and Beverage | In-kind items and services | GVOKE HYPOPEN Drug, Diabetes | 2025 | |
| 2025-03-04 | Novo Nordisk Inc | $12 | Food and Beverage | In-kind items and services | Wegovy Drug, Obesity | 2025 | |
| 2025-02-27 | Novo Nordisk Inc | $20 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-02-25 | Ascendis Pharma Endocrinology Inc | $22 | Food and Beverage | In-kind items and services | Yorvipath Drug, Endocrinology | 2025 | |
| 2025-02-19 | Novo Nordisk Inc | $12 | Food and Beverage | In-kind items and services | Wegovy Drug, Obesity | 2025 | |
| 2025-02-18 | Boehringer Ingelheim Pharmaceuticals, Inc. | $20 | Food and Beverage | In-kind items and services | JARDIANCE Drug, DIABETES | 2025 | |
| 2025-02-18 | Novo Nordisk Inc | $8 | Food and Beverage | In-kind items and services | Rybelsus Drug, Diabetes | 2025 | |
| 2025-02-11 | Tandem Diabetes Care, Inc. | $17 | Food and Beverage | In-kind items and services | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2025 | |
| 2025-02-06 | SANOFI-AVENTIS U.S. LLC | $29 | Food and Beverage | In-kind items and services | TZIELD Biological, Endocrine & Metabolic Diseases | 2025 | |
| 2025-02-05 | Dexcom, Inc. | $5,362 | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | DEXCOM G7 GSS (161) Medical Supply, Endocrinology | 2025 | |
| 2025-02-05 | Mannkind Corporation | $18 | Food and Beverage | In-kind items and services | AFREZZA Drug, DIABETES MEDICINE | 2025 | |
| 2025-02-04 | Novo Nordisk Inc | $13 | Food and Beverage | In-kind items and services | Wegovy Drug, Obesity | 2025 | |
| 2025-01-31 | Dexcom, Inc. | $96 | Travel and Lodging | In-kind items and services | DEXCOM G7 GSS (161) Medical Supply, Endocrinology | 2025 | |
| 2025-01-28 | Dexcom, Inc. | $172 | Travel and Lodging | In-kind items and services | DEXCOM G7 GSS (161) Medical Supply, Endocrinology | 2025 | |
| 2025-01-28 | Verity Pharmaceuticals Inc. | $23 | Food and Beverage | Cash or cash equivalent | Tlando Drug, Testosterone Replacement Therapy (TRT) | 2025 | |
| 2025-01-15 | Ascendis Pharma Endocrinology Inc | $22 | Food and Beverage | In-kind items and services | Yorvipath Drug, Endocrinology | 2025 | |
| 2025-01-14 | Boehringer Ingelheim Pharmaceuticals, Inc. | $18 | Food and Beverage | In-kind items and services | JARDIANCE Drug, DIABETES | 2025 | |
| 2025-01-13 | Dexcom, Inc. | $581 | Travel and Lodging | In-kind items and services | DEXCOM G7 GSS (161) Medical Supply, Endocrinology | 2025 | |
| 2025-01-09 | Esperion Therapeutics, Inc. | $14 | Food and Beverage | In-kind items and services | NEXLETOL Drug, ANTILIPEMIC AGENTS | 2025 | |
| 2025-01-09 | Echosens North America, Inc. | $8 | Food and Beverage | Cash or cash equivalent | Fibroscan Device, Elastography | 2025 | |
| 2024-12-23 | Abbott Laboratories | $14 | Food and Beverage | In-kind items and services | FREESTYLE LIBRE 3 Device, Diabetes Care | 2024 | |
| 2024-12-19 | SANOFI-AVENTIS U.S. LLC | $26 | Food and Beverage | In-kind items and services | TZIELD Biological, Endocrine & Metabolic Diseases | 2024 | |
| 2024-12-18 | Novo Nordisk Inc | $7 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2024 | |
| 2024-12-12 | Mannkind Corporation | $16 | Food and Beverage | In-kind items and services | AFREZZA Drug, DIABETES MEDICINE | 2024 | |
| 2024-12-12 | Xeris Pharmaceuticals, Inc. | $7 | Food and Beverage | In-kind items and services | GVOKE HYPOPEN Drug, Diabetes | 2024 | |
| 2024-12-04 | Insulet Corporation | $6 | Food and Beverage | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2024 | |
| 2024-12-03 | Lilly USA, LLC | $18 | Food and Beverage | In-kind items and services | JARDIANCE Drug, Diabetes | 2024 | |
| 2024-12-02 | Lilly USA, LLC | $45 | Travel and Lodging | Cash or cash equivalent | JARDIANCE Drug, Diabetes | 2024 | |
| 2024-12-02 | Xeris Pharmaceuticals, Inc. | $21 | Food and Beverage | In-kind items and services | GVOKE HYPOPEN Drug, Diabetes | 2024 | |
| 2024-11-21 | Amgen Inc. | $142 | Food and Beverage | In-kind items and services | TEPEZZA Biological, Inflammation/Rare Disease | 2024 | |
| 2024-11-21 | Insulet Corporation | $5 | Food and Beverage | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2024 | |
| 2024-11-19 | Novo Nordisk Inc | $21 | Food and Beverage | In-kind items and services | Rybelsus Drug, Diabetes | 2024 | |
| 2024-11-14 | RECORDATI_RARE_DISEASES_INC. | $20 | Food and Beverage | In-kind items and services | SIGNIFOR LAR Drug, ENDOCRINE AGENT | 2024 | |
| 2024-11-12 | Novo Nordisk Inc | $16 | Food and Beverage | In-kind items and services | Wegovy Drug, Obesity | 2024 | |
| 2024-11-06 | Xeris Pharmaceuticals, Inc. | $20 | Food and Beverage | In-kind items and services | GVOKE HYPOPEN Drug, Diabetes | 2024 | |
| 2024-11-05 | Antares Pharma, Inc. | $17 | Food and Beverage | In-kind items and services | XYOSTED Drug, TESTOSTERONE REPLACEMENT THERAPY | 2024 | |
| 2024-11-01 | Lilly USA, LLC | $800 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | JARDIANCE Drug, Diabetes | 2024 | |
| 2024-11-01 | Lilly USA, LLC | $800 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | JARDIANCE Drug, Diabetes | 2024 | |
| 2024-10-30 | Lilly USA, LLC | $21 | Food and Beverage | In-kind items and services | JARDIANCE Drug, Diabetes | 2024 | |
| 2024-10-30 | Insulet Corporation | $21 | Food and Beverage | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2024 | |
| 2024-10-29 | Ascensia Diabetes Care Us Inc. | $18 | Food and Beverage | In-kind items and services | EVERSENSE 365 SENSOR KIT (RETAIL) Device, Diabetes | 2024 | |
| 2024-10-17 | ABBVIE INC. | $10 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-10-16 | Lilly USA, LLC | $900 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | MOUNJARO Drug, Diabetes | 2024 | |
| 2024-10-16 | Antares Pharma, Inc. | $19 | Food and Beverage | In-kind items and services | XYOSTED Drug, TESTOSTERONE REPLACEMENT THERAPY | 2024 | |
| 2024-10-15 | KYOWA KIRIN, INC. | $17 | Food and Beverage | In-kind items and services | Crysvita Drug, fibroblast growth factor 23 (FGF23) blocking antibody. | 2024 | |
| 2024-10-15 | Corcept Therapeutics | $14 | Food and Beverage | In-kind items and services | Korlym Drug, Endocrinology | 2024 | |
| 2024-10-10 | Amgen Inc. | $26 | Food and Beverage | In-kind items and services | TEPEZZA Biological, Inflammation/Rare Disease | 2024 | |
| 2024-10-09 | Novo Nordisk Inc | $13 | Food and Beverage | In-kind items and services | Wegovy Drug, Obesity | 2024 | |
| 2024-10-08 | Abbott Laboratories | $20 | Food and Beverage | In-kind items and services | FREESTYLE LIBRE 3 Device, Diabetes Care | 2024 | |
| 2024-10-08 | Insulet Corporation | $7 | Food and Beverage | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2024 | |
| 2024-10-03 | Lilly USA, LLC | $800 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | JARDIANCE Drug, Diabetes | 2024 | |
| 2024-10-03 | SANOFI-AVENTIS U.S. LLC | $22 | Food and Beverage | In-kind items and services | TZIELD Biological, Endocrine & Metabolic Diseases | 2024 | |
| 2024-10-02 | Novo Nordisk Inc | $23 | Food and Beverage | In-kind items and services | Rybelsus Drug, Diabetes | 2024 | |
| 2024-10-02 | Xeris Pharmaceuticals, Inc. | $15 | Food and Beverage | In-kind items and services | GVOKE HYPOPEN Drug, Diabetes | 2024 | |
| 2024-09-24 | Eli Lilly and Company | $692 | Research payment | Cash or cash equivalent | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION | 2024 | |
| 2024-09-19 | Astellas Pharma US Inc | $99 | Education | In-kind items and services | 2024 | ||
| 2024-09-12 | Alexion Pharmaceuticals, Inc. | $22 | Food and Beverage | In-kind items and services | STRENSIQ Biological, Rare Disease | 2024 | |
| 2024-09-05 | Embecta Corp. | $20 | Food and Beverage | In-kind items and services | BD Nano 2nd Gen Pen Needle Device, Diabetes Care | 2024 | |
| 2024-09-05 | Novo Nordisk Inc | $6 | Food and Beverage | In-kind items and services | Wegovy Drug, Obesity | 2024 | |
| 2024-09-03 | Verity Pharmaceuticals Inc. | $23 | Food and Beverage | Cash or cash equivalent | Tlando Drug, Testosterone Replacement Therapy (TRT) | 2024 | |
| 2024-08-29 | Lilly USA, LLC | $19 | Food and Beverage | In-kind items and services | MOUNJARO Drug, Diabetes | 2024 | |
| 2024-08-28 | Dexcom, Inc. | $28 | Food and Beverage | In-kind items and services | Dexcom G6 Transmitter Medical Supply, Endocrinology | 2024 | |
| 2024-08-27 | Novo Nordisk Inc | $18 | Food and Beverage | In-kind items and services | Rybelsus Drug, Diabetes | 2024 | |
| 2024-08-27 | Tandem Diabetes Care, Inc. | $17 | Food and Beverage | In-kind items and services | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2024 | |
| 2024-08-22 | Insulet Corporation | $20 | Food and Beverage | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2024 | |
| 2024-08-21 | SANOFI-AVENTIS U.S. LLC | $23 | Food and Beverage | In-kind items and services | TZIELD Biological, Endocrine & Metabolic Diseases | 2024 | |
| 2024-08-21 | Lilly USA, LLC | $16 | Food and Beverage | In-kind items and services | JARDIANCE Drug, Diabetes | 2024 | |
| 2024-08-20 | Novo Nordisk Inc | $4 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-08-12 | Lilly USA, LLC | $1,800 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | MOUNJARO Drug, Diabetes | 2024 | |
| 2024-08-12 | Lilly USA, LLC | $1,125 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | MOUNJARO Drug, Diabetes | 2024 | |
| 2024-08-10 | Lilly USA, LLC | $15 | Food and Beverage | In-kind items and services | MOUNJARO Drug, Diabetes | 2024 | |
| 2024-08-09 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | JARDIANCE Drug, DIABETES | 2024 | |
| 2024-08-08 | Corcept Therapeutics | $21 | Food and Beverage | In-kind items and services | Korlym Drug, Endocrinology | 2024 | |
| 2024-08-06 | Alexion Pharmaceuticals, Inc. | $109 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-08-06 | Lilly USA, LLC | $16 | Food and Beverage | In-kind items and services | MOUNJARO Drug, Diabetes | 2024 | |
| 2024-08-01 | Esperion Therapeutics, Inc. | $23 | Food and Beverage | In-kind items and services | NEXLETOL Drug, ANTILIPEMIC AGENTS | 2024 | |
| 2024-08-01 | Insulet Corporation | $7 | Food and Beverage | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2024 | |
| 2024-07-25 | Lilly USA, LLC | $31 | Food and Beverage | In-kind items and services | MOUNJARO Drug, Diabetes | 2024 | |
| 2024-07-24 | Lilly USA, LLC | $800 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | JARDIANCE Drug, Diabetes | 2024 | |
| 2024-07-24 | Antares Pharma, Inc. | $19 | Food and Beverage | In-kind items and services | XYOSTED Drug, TESTOSTERONE REPLACEMENT THERAPY | 2024 | |
| 2024-07-23 | Novo Nordisk Inc | $18 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2024 | |
| 2024-07-23 | Novo Nordisk Inc | $12 | Food and Beverage | In-kind items and services | Wegovy Drug, Obesity | 2024 | |
| 2024-07-23 | Abbott Laboratories | $11 | Food and Beverage | In-kind items and services | FREESTYLE LIBRE 3 Device, Diabetes Care | 2024 | |
| 2024-07-18 | Insulet Corporation | $19 | Food and Beverage | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2024 | |
| 2024-07-17 | Averitas Pharma Inc. | $28 | Food and Beverage | In-kind items and services | QUTENZA Drug, PAIN MANAGEMENT | 2024 | |
| 2024-07-16 | Lilly USA, LLC | $21 | Food and Beverage | In-kind items and services | LYUMJEV Drug, Diabetes | 2024 | |
| 2024-06-19 | Xeris Pharmaceuticals, Inc. | $23 | Food and Beverage | In-kind items and services | GVOKE HYPOPEN Drug, Diabetes | 2024 | |
| 2024-06-19 | Novo Nordisk Inc | $18 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2024 | |
| 2024-06-14 | Lilly USA, LLC | $25 | Food and Beverage | In-kind items and services | MOUNJARO Drug, Diabetes | 2024 | |
| 2024-06-13 | Insulet Corporation | $19 | Food and Beverage | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2024 | |
| 2024-06-11 | Verity Pharmaceuticals Inc. | $29 | Food and Beverage | Cash or cash equivalent | Tlando Drug, Testosterone Replacement Therapy (TRT) | 2024 | |
| 2024-06-05 | Medtronic, Inc. | $15 | Food and Beverage | In-kind items and services | MINIMED 780G Device, Durable Pump | 2024 | |
| 2024-06-05 | Mannkind Corporation | $13 | Food and Beverage | In-kind items and services | AFREZZA Drug, DIABETES MEDICINE | 2024 | |
| 2024-06-04 | Lilly USA, LLC | $7 | Food and Beverage | In-kind items and services | MOUNJARO Drug, Diabetes | 2024 | |
| 2024-06-04 | Xeris Pharmaceuticals, Inc. | $3 | Food and Beverage | In-kind items and services | GVOKE HYPOPEN Drug, Diabetes | 2024 | |
| 2024-06-03 | Boehringer Ingelheim Pharmaceuticals, Inc. | $800 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | JARDIANCE Drug, DIABETES | 2024 | |
| 2024-06-02 | SANOFI-AVENTIS U.S. LLC | $48 | Food and Beverage | In-kind items and services | TZIELD Biological, Endocrine & Metabolic Diseases | 2024 | |
| 2024-05-30 | Lilly USA, LLC | $900 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | MOUNJARO Drug, Diabetes | 2024 | |
| 2024-05-23 | Lilly USA, LLC | $900 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | MOUNJARO Drug, Diabetes | 2024 | |
| 2024-05-23 | Novo Nordisk Inc | $20 | Food and Beverage | In-kind items and services | Wegovy Drug, Obesity | 2024 | |
| 2024-05-22 | Mannkind Corporation | $67 | Food and Beverage | In-kind items and services | AFREZZA Drug, DIABETES MEDICINE | 2024 |
The latest 200 records of 1,865.
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2025-12-31 | ABBVIE INC. | EAST COAST INSTITUTE FOR RESEARCH JACKSONVILLE | $5,520 | A Phase 2/3 multicenter, double blinded, randomized, dose-conversion, active control study examining the efficacy and sa | 2025 |
| 2025-11-05 | ABBVIE INC. | EAST COAST INSTITUTE FOR RESEARCH | $4,130 | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary H | 2025 |
| 2025-10-15 | AstraZeneca Pharmaceuticals LP | ECIR MEDICAL COMMUNICATIONS | $20,790 | A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Effect of AZD0780 on Major | 2025 |
| 2025-10-09 | ABBVIE INC. | EAST COAST INSTITUTE FOR RESEARCH | $1,960 | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary H | 2025 |
| 2025-09-24 | AstraZeneca Pharmaceuticals LP | ECIR MEDICAL COMMUNICATIONS | $21,790 | a phase third,randomised,double blind,placebo controlled,eventdriven study to evaluate the effect of baxdrostat in combi | 2025 |
| 2025-09-04 | ABBVIE INC. | EAST COAST INSTITUTE FOR RESEARCH | $14,672 | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary H | 2025 |
| 2025-08-13 | Alnylam Pharmaceuticals Inc. | EAST COAST INSTITUTE FOR RESEARCH, LLC | $324 | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2025 |
| 2025-08-13 | Alnylam Pharmaceuticals Inc. | EAST COAST INSTITUTE FOR RESEARCH, LLC | $244 | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2025 |
| 2025-08-13 | Alnylam Pharmaceuticals Inc. | EAST COAST INSTITUTE FOR RESEARCH, LLC | $416 | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2025 |
| 2025-08-06 | ABBVIE INC. | EAST COAST INSTITUTE FOR RESEARCH | $27,647 | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary H | 2025 |
| 2025-07-28 | Amgen Inc. | EAST COAST INSTITUTE FOR RESEARCH, LLC | $9,778 | A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiov | 2025 |
| 2025-07-16 | AstraZeneca UK Limited | EAST COAST INSTITUTE FOR RESEARCH, LLC | $35,310 | A Phase II Randomised Double blind Placebo controlled Study to Evaluate the Efficacy Safety and Tolerability of AZD6234 | 2025 |
| 2025-07-14 | Alnylam Pharmaceuticals Inc. | EAST COAST INSTITUTE FOR RESEARCH, LLC | $2,037 | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2025 |
| 2025-07-14 | Alnylam Pharmaceuticals Inc. | EAST COAST INSTITUTE FOR RESEARCH, LLC | $2,037 | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2025 |
| 2025-07-14 | Alnylam Pharmaceuticals Inc. | EAST COAST INSTITUTE FOR RESEARCH, LLC | $1,500 | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2025 |
| 2025-07-14 | Alnylam Pharmaceuticals Inc. | EAST COAST INSTITUTE FOR RESEARCH, LLC | $1,895 | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2025 |
| 2025-07-14 | Alnylam Pharmaceuticals Inc. | EAST COAST INSTITUTE FOR RESEARCH, LLC | $1,499 | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2025 |
| 2025-07-08 | Amgen Inc. | EAST COAST INSTITUTE FOR RESEARCH, LLC | $47,172 | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardio | 2025 |
| 2025-07-02 | ABBVIE INC. | EAST COAST INSTITUTE FOR RESEARCH | $17,921 | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary H | 2025 |
| 2025-06-17 | ABBVIE INC. | EAST COAST INSTITUTE FOR RESEARCH | $1,500 | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary H | 2025 |
| 2025-06-12 | ABBVIE INC. | EAST COAST INSTITUTE FOR RESEARCH | $3,500 | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary H | 2025 |
| 2025-06-03 | ABBVIE INC. | EAST COAST INSTITUTE FOR RESEARCH | $38,287 | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary H | 2025 |
| 2025-05-29 | Medtronic, Inc. | East Coast Institute for Research LLC | $3,500 | CIP341 IMPACT2 | 2025 |
| 2025-05-07 | ABBVIE INC. | EAST COAST INSTITUTE FOR RESEARCH | $5,934 | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary H | 2025 |
| 2025-04-11 | Ascendis Pharma Endocrinology Inc | Georgia Mountain Endocrinology, Corp | $369 | EAP of Palopegteriparatide in Patients With Hypoparathyroidism | 2025 |
| 2025-04-11 | Ascendis Pharma Endocrinology Inc | Georgia Mountain Endocrinology, Corp | $263 | EAP of Palopegteriparatide in Patients With Hypoparathyroidism | 2025 |
| 2025-04-11 | Ascendis Pharma Endocrinology Inc | Georgia Mountain Endocrinology, Corp | $263 | EAP of Palopegteriparatide in Patients With Hypoparathyroidism | 2025 |
| 2025-04-11 | Ascendis Pharma Endocrinology Inc | Georgia Mountain Endocrinology, Corp | $263 | EAP of Palopegteriparatide in Patients With Hypoparathyroidism | 2025 |
| 2025-04-11 | Ascendis Pharma Endocrinology Inc | Georgia Mountain Endocrinology, Corp | $463 | EAP of Palopegteriparatide in Patients With Hypoparathyroidism | 2025 |
| 2025-04-11 | Ascendis Pharma Endocrinology Inc | Georgia Mountain Endocrinology, Corp | $263 | EAP of Palopegteriparatide in Patients With Hypoparathyroidism | 2025 |
| 2025-04-11 | Ascendis Pharma Endocrinology Inc | Georgia Mountain Endocrinology, Corp | $263 | EAP of Palopegteriparatide in Patients With Hypoparathyroidism | 2025 |
| 2025-04-03 | Medtronic, Inc. | East Coast Institute for Research LLC | $103 | CIP341 IMPACT2 | 2025 |
| 2025-04-03 | ABBVIE INC. | EAST COAST INSTITUTE FOR RESEARCH | $19,124 | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary H | 2025 |
| 2025-04-03 | Medtronic, Inc. | East Coast Institute for Research LLC | $729 | CIP341 IMPACT2 | 2025 |
| 2025-03-07 | ABBVIE INC. | EAST COAST INSTITUTE FOR RESEARCH | $14,700 | M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of | 2025 |
| 2025-02-25 | Eli Lilly and Company | EAST COAST INSTITUTE FOR RESEARCH | $752 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION | 2025 |
| 2025-02-13 | Medtronic, Inc. | East Coast Institute for Research LLC | $500 | CIP341 IMPACT2 | 2025 |
| 2025-02-13 | Medtronic, Inc. | East Coast Institute for Research LLC | $375 | CIP341 IMPACT2 | 2025 |
| 2025-02-13 | Medtronic, Inc. | East Coast Institute for Research LLC | $550 | CIP341 IMPACT2 | 2025 |
| 2025-02-06 | ABBVIE INC. | EAST COAST INSTITUTE FOR RESEARCH | $10,850 | M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of | 2025 |
| 2025-01-27 | Novartis Pharmaceuticals Corporation | EAST COAST INSTITUTE FOR RESEARCH CANTON | $6,903 | A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Majo | 2025 |
| 2025-01-21 | Eli Lilly and Company | EAST COAST INSTITUTE FOR RESEARCH | $73,812 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION | 2025 |
| 2025-01-13 | ABBVIE INC. | EAST COAST INSTITUTE FOR RESEARCH | $2,190 | M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of | 2025 |
| 2025-01-07 | Novartis Pharmaceuticals Corporation | EAST COAST INSTITUTE FOR RESEARCH | $6,304 | A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Majo | 2025 |
| 2025-01-02 | ABBVIE INC. | EAST COAST INSTITUTE FOR RESEARCH | $3,304 | M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of | 2025 |
| 2024-12-31 | ABBVIE INC. | EAST COAST INSTITUTE FOR RESEARCH | $4,992 | M21-341 ATH Ph 2b Armour Thyroid vs Synthetic T4 (ATH-MD-01) (3014-301-002) | 2024 |
| 2024-12-05 | ABBVIE INC. | EAST COAST INSTITUTE FOR RESEARCH | $7,315 | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary H | 2024 |
| 2024-11-07 | ABBVIE INC. | EAST COAST INSTITUTE FOR RESEARCH | $10,525 | A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Sa | 2024 |
| 2024-11-01 | Medtronic, Inc. | East Coast Institute for Research LLC | $875 | CIP341 IMPACT2 | 2024 |
| 2024-10-31 | Alnylam Pharmaceuticals Inc. | East Coast Institute For Research,LLC_Canton | $30 | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2024 |
| 2024-10-31 | Alnylam Pharmaceuticals Inc. | East Coast Institute For Research,LLC_Canton | $55 | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2024 |
| 2024-10-31 | Alnylam Pharmaceuticals Inc. | East Coast Institute For Research,LLC_Canton | $55 | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2024 |
| 2024-10-03 | ABBVIE INC. | EAST COAST INSTITUTE FOR RESEARCH | $31,097 | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary H | 2024 |
| 2024-09-30 | Alnylam Pharmaceuticals Inc. | East Coast Institute For Research,LLC_Canton | $30 | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2024 |
| 2024-09-30 | Alnylam Pharmaceuticals Inc. | East Coast Institute For Research,LLC_Canton | $55 | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2024 |
| 2024-09-30 | Alnylam Pharmaceuticals Inc. | East Coast Institute For Research,LLC_Canton | $55 | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2024 |
| 2024-09-18 | Medtronic, Inc. | East Coast Institute for Research LLC | $72,943 | CIP341 IMPACT2 | 2024 |
| 2024-09-13 | Alnylam Pharmaceuticals Inc. | East Coast Institute for Research at Baker Gilmour Cardiovascular Institute | $500 | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2024 |
| 2024-09-13 | Alnylam Pharmaceuticals Inc. | East Coast Institute for Research at Baker Gilmour Cardiovascular Institute | $375 | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2024 |
| 2024-09-11 | Bayer Healthcare Pharmaceuticals Inc. | ACADEMIC MEDICAL RESEARCH INSTITUTE | $1,235 | BAY 948862, A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finereno | 2024 |
| 2024-09-09 | Alnylam Pharmaceuticals Inc. | East Coast Institute for Research at Baker Gilmour Cardiovascular Institute | $183 | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2024 |
| 2024-09-09 | Alnylam Pharmaceuticals Inc. | East Coast Institute for Research at Baker Gilmour Cardiovascular Institute | $416 | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2024 |
| 2024-09-04 | ABBVIE INC. | EAST COAST INSTITUTE FOR RESEARCH | $41,554 | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary H | 2024 |
| 2024-08-30 | Alnylam Pharmaceuticals Inc. | East Coast Institute For Research,LLC_Canton | $30 | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2024 |
| 2024-08-30 | Alnylam Pharmaceuticals Inc. | East Coast Institute For Research,LLC_Canton | $55 | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2024 |
| 2024-08-30 | Alnylam Pharmaceuticals Inc. | East Coast Institute For Research,LLC_Canton | $55 | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2024 |
| 2024-08-05 | Medtronic, Inc. | East Coast Institute for Research LLC | $875 | CIP341 IMPACT2 | 2024 |
| 2024-08-02 | ABBVIE INC. | EAST COAST INSTITUTE FOR RESEARCH | $23,963 | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary H | 2024 |
| 2024-08-02 | Alnylam Pharmaceuticals Inc. | East Coast Institute for Research at Baker Gilmour Cardiovascular Institute | $416 | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2024 |
| 2024-08-02 | Alnylam Pharmaceuticals Inc. | East Coast Institute for Research at Baker Gilmour Cardiovascular Institute | $162 | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2024 |
| 2024-08-02 | Alnylam Pharmaceuticals Inc. | East Coast Institute for Research at Baker Gilmour Cardiovascular Institute | $362 | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2024 |
| 2024-07-31 | Alnylam Pharmaceuticals Inc. | East Coast Institute For Research,LLC_Canton | $30 | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2024 |
| 2024-07-31 | Alnylam Pharmaceuticals Inc. | East Coast Institute For Research,LLC_Canton | $55 | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2024 |
| 2024-07-31 | Alnylam Pharmaceuticals Inc. | East Coast Institute For Research,LLC_Canton | $55 | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2024 |
| 2024-07-16 | Eli Lilly and Company | EAST COAST INSTITUTE FOR RESEARCH | $50,649 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION | 2024 |
| 2024-07-12 | Bayer Healthcare Pharmaceuticals Inc. | ACADEMIC MEDICAL RESEARCH INSTITUTE | $4,550 | BAY 948862, A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finereno | 2024 |
| 2024-07-02 | Medtronic, Inc. | East Coast Institute for Research LLC | $1,833 | CIP341 IMPACT2 | 2024 |
| 2024-06-28 | Alnylam Pharmaceuticals Inc. | East Coast Institute For Research,LLC_Canton | $30 | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2024 |
| 2024-06-28 | Alnylam Pharmaceuticals Inc. | East Coast Institute For Research,LLC_Canton | $55 | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2024 |
| 2024-06-28 | Alnylam Pharmaceuticals Inc. | East Coast Institute For Research,LLC_Canton | $55 | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2024 |
| 2024-06-03 | Alnylam Pharmaceuticals Inc. | East Coast Institute for Research at Baker Gilmour Cardiovascular Institute | $109 | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2024 |
| 2024-06-03 | Alnylam Pharmaceuticals Inc. | East Coast Institute for Research at Baker Gilmour Cardiovascular Institute | $14,573 | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2024 |
| 2024-06-03 | Alnylam Pharmaceuticals Inc. | East Coast Institute for Research at Baker Gilmour Cardiovascular Institute | $232 | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2024 |
| 2024-06-03 | Alnylam Pharmaceuticals Inc. | East Coast Institute for Research at Baker Gilmour Cardiovascular Institute | $405 | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2024 |
| 2024-06-03 | Alnylam Pharmaceuticals Inc. | East Coast Institute for Research at Baker Gilmour Cardiovascular Institute | $1,090 | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2024 |
| 2024-05-31 | Alnylam Pharmaceuticals Inc. | East Coast Institute For Research,LLC_Canton | $55 | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2024 |
| 2024-05-31 | Alnylam Pharmaceuticals Inc. | East Coast Institute For Research,LLC_Canton | $55 | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2024 |
| 2024-05-31 | Alnylam Pharmaceuticals Inc. | East Coast Institute For Research,LLC_Canton | $30 | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2024 |
| 2024-05-21 | Medtronic, Inc. | East Coast Institute for Research LLC | $556 | CIP341 IMPACT2 | 2024 |
| 2024-05-15 | Eli Lilly and Company | EAST COAST INSTITUTE FOR RESEARCH | $4,763 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION | 2024 |
| 2024-05-13 | Medtronic, Inc. | East Coast Institute for Research LLC | $875 | CIP341 IMPACT2 | 2024 |
| 2024-05-09 | ABBVIE INC. | EAST COAST INSTITUTE FOR RESEARCH | $14,500 | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary H | 2024 |
| 2024-05-03 | Bayer Healthcare Pharmaceuticals Inc. | ACADEMIC MEDICAL RESEARCH INSTITUTE | $5,720 | BAY 948862, A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finereno | 2024 |
| 2024-04-30 | Alnylam Pharmaceuticals Inc. | East Coast Institute For Research,LLC_Canton | $30 | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2024 |
| 2024-04-30 | Alnylam Pharmaceuticals Inc. | East Coast Institute For Research,LLC_Canton | $55 | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2024 |
| 2024-04-30 | Alnylam Pharmaceuticals Inc. | East Coast Institute For Research,LLC_Canton | $55 | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2024 |
| 2024-04-22 | Alnylam Pharmaceuticals Inc. | East Coast Institute for Research at Baker Gilmour Cardiovascular Institute | $109 | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2024 |
| 2024-04-22 | Alnylam Pharmaceuticals Inc. | East Coast Institute for Research at Baker Gilmour Cardiovascular Institute | $116 | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2024 |
| 2024-04-15 | Medtronic, Inc. | East Coast Institute for Research LLC | $943 | CIP341 IMPACT2 | 2024 |
| 2024-03-29 | Alnylam Pharmaceuticals Inc. | East Coast Institute For Research,LLC_Canton | $55 | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2024 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Jasper, GA, county Pickens County, GA, state Georgia; placed by its city name.
| Measure | Place (city or town) Jasper, GA | County Pickens County, GA | State Georgia |
|---|---|---|---|
| Population B01003 | 4,630 | 34,951 | 10,940,407 |
| Population, 2020 census P1 | 4,084 | 33,216 | 10,711,908 |
| Median age B01002 | 30.2 | 46.7 | 37.6 |
| Under 18 B01001 | 28.3% | 18.8% | 23.2% |
| 65 and over B01001 | 18.3% | 23.0% | 15.0% |
| Households B11001 | 1,694 | 13,430 | 4,074,366 |
| Foreign born B05002 | 2.3% | 2.8% | 11.2% |
| Median household income B19013 | $52,442 | $78,930 | $77,353 |
| Median family income B19113 | $50,833 | $95,242 | $93,754 |
| Per capita income B19301 | $27,816 | $40,871 | $40,924 |
| Poverty rate B17001 | 27.2% | 12.0% | 13.4% |
| Unemployment rate B23025 | 0.1% | 3.0% | 5.1% |
| Civilian labor force B23025 | 1,924 | 17,000 | 5,496,061 |
| Mean commute (minutes) B08013 | 30.4 | 33.5 | 28.3 |
| Bachelor's degree or higher B15003 | 17.7% | 26.7% | 34.9% |
| Housing units B25001 | 1,937 | 15,561 | 4,541,835 |
| Owner-occupied B25003 | 50.4% | 81.2% | 65.7% |
| Renters B25003 | 49.6% | 18.8% | 34.3% |
| Median home value B25077 | $282,500 | $332,700 | $303,300 |
| Median gross rent B25064 | $1,122 | $1,136 | $1,393 |
| White, not Hispanic B03002 | 88.7% | 91.5% | 49.1% |
| Black B03002 | 0.5% | 0.6% | 30.7% |
| Hispanic or Latino B03002 | 5.9% | 4.0% | 11.0% |
| Asian B03002 | 0.4% | 0.3% | 4.5% |
| American Indian and Alaska Native B03002 | 0.0% | 0.2% | 0.1% |
Economy now FRED unemployment 3.3% in Sep 2026 (3.4% a year earlier); per capita personal income $65,111 in 2025, up 26% in five years (+1.6% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Jasper, GA.
Comments